ReviewMedical oncology (Northwood, London, England)2025
Effects of bioactive compounds from marine algae on cancer-related inflammation: a review.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.Molecular biology reports · 2026Review
- Decreased expression of immune activator WARS1 and other pro-inflammatory mediators in type 1-like macrophages as an associated mode of action in response to fucoidan from marine brown algae.Frontiers in immunology · 2026Article
- The potential regulation mechanism of lily extracts responds to AAPH induced oxidative stress in zebrafish.Food chemistry. Molecular sciences · 2025Article
- Prospects and challenges of novel natural marine-derived compounds in melanoma treatment.World journal of clinical oncology · 2025Review
- Bioactive compounds from marine algae in pancreatic cancer therapy: mechanistic insights into fucoidan and phlorotannins: a review.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine macroalgae serve as a substantial source of bioactive compounds with potential health advantages, especially in anticancer properties. Their anti-inflammatory characteristics, especially concerning cancer, are significant due to their potential application in the management of chronic inflammatory illnesses such as cancer. Nevertheless, limited studies have documented the anti-inflammatory effects of compounds derived from marine macroalgae. This review seeks to aggregate and synthesize current research on the anti-inflammatory properties of bioactive compounds derived from marine macroalgae. A comprehensive examination of web databases, including PubMed, Scopus, and Web of Science, was performed to locate pertinent content. Numerous bioactive compounds, including polyphenols, polysaccharides, terpenoids, and fatty acids, are acknowledged as important factors in the anti-inflammatory properties of marine macroalgae in cancer. These compounds exert their effects by several molecular mechanisms, including the suppression of pro-inflammatory cytokines, downregulation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways, and regulation of oxidative stress. Species of brown, green, and red macroalgae, including Laminaria sp., Gracilaria sp., and Ulva sp., demonstrate considerable anti-inflammatory properties in cancer. Additional standardized research, especially clinical trials, is necessary to validate their translational potential. This review seeks to systematically examine and integrate existing research on bioactive substances from marine macroalgae that possess anti-inflammatory activities pertinent to cancer therapy, emphasizing their origins, mechanisms of action, and therapeutic potential, while also identifying research deficiencies and future avenues for clinical application.
Indexed as
Identifiers
40498177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.